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Abstract Success with recent immunotherapies has resulted
in previously unattainable response rates, as well as durable
responses in diseases with historically poor prognoses. The
combination of radiation therapy and immunotherapy has
been a recent area of active investigation, with exciting results
in a subset of patients. However, patient characteristics pre-
dictive of probable benefit from therapy and clinically mean-
ingful biomarkers indicative of the early development of an
antitumor immune response have yet to be identified. What is
needed is a better way to predict which patients are likely to
benefit from therapy, which would allow those patients un-
likely to benefit from immunotherapy to be spared potentially
futile therapies, thereby avoiding unnecessary risks of toxicity
and costly treatment. Here, we summarize the early data on
predictors of clinical response to immunotherapy, and to im-
munotherapy in combination with radiation.
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Introduction
Success with recent immunotherapies has resulted in previ-
ously unattainable response rates, as well as durable responses
in diseases with historically poor prognoses. The combination
of radiation therapy and immunotherapy has been a recent
area of active investigation, with exciting results in a subset
of patients. However, patient characteristics predictive of
probable benefit from therapy and clinically meaningful bio-
markers indicative of the early development of an antitumor
immune response have yet to be identified.What is needed is a
better way to predict which patients are likely to benefit from
therapy, which would allow those patients unlikely to benefit
from immunotherapy to be spared potentially futile therapies,
thereby avoiding unnecessary risks of toxicity and costly treat-
ment. Here, we summarize the early data on predictors of
clinical response to immunotherapy, and to immunotherapy
in combination with radiation.
Recent advances in immunotherapy in treating
malignancy
There has been significant recent interest in strategies designed
to modulate the immune system in order to elicit and enhance
an antitumor immune response. One of the early successes in
this area has been in the targeting of cytotoxic T-lymphocyte-
associated protein-4 (CTLA-4). CTLA-4 is a molecule
expressed by activated Tcells that competes with CD28 signal-
ing on T cells, with its activation resulting in decreased T cell
activation and proliferation. Ipilimumab, a monoclonal anti-
body directed against CTLA-4, was the first drug to show im-
proved overall survival in patients with advanced melanoma
[17] and has also shown single-agent activity in other malig-
nancies. However, toxicity associated with ipilimumab is not
insignificant and many patients do not respond to therapy.
Preclinical and early clinical studies targeting the programmed
death-1 receptor (PD-1), another T cell coinhibitory receptor,
have shown even better response rates and lower toxicity than
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ipilimumab. PD-1 is expressed on activated T and B cells and
has two identified ligands, programmed death-ligand 1 (PD-
L1) and programmed death ligand-2 (PD-L2). Its primary li-
gand is PD-L1, expressed on a subset of hematopoietic and
nonhematopoietic cells, which has been reported to be regulat-
ed by pro-inflammatory cytokines [39]. Multiple reports of
anti-PD-1 therapy have shown promising results in the clinic
in treating patients with advanced melanoma and other malig-
nancies. In a study primarily composed of heavily pretreated
patients with advanced melanoma and renal cell carcinoma, as
well as patients with non-small cell lung cancer (NSCLC),
castrate-resistant prostate cancer, and colorectal cancer (CRC),
patients were treated with the anti-PD-1 targeted therapy
nivolumab. Twenty-eight percent of patients experienced dura-
ble objective tumor responses. A subset analysis of patients
with NSCLC revealed an objective response rate of 18 % [40].
Other studies have shown similarly promising results. For
example, a large phase I trial with the anti-PD-1 antibody MK-
3475 (pembrolizumab) had a response rate of 38 % in patients
with advanced melanoma [13]. Another study of
pembrolizumab showed an overall response rate of 26 % in
patients who had experienced progression of disease on
ipilimumab [33]. In the largest study of PD-1-directed therapy
published to date, the KEYNOTE-006 randomized phase III
trial, 834 patients with advanced melanoma received either
pembrolizumab every 2 or 3 weeks or ipilimumab every
3 weeks. Both pembrolizumab groups had better PFS and OS
as compared with the ipilimumab group, with less high-grade
toxicity [34]. Finally, in a randomized double-blind study of
142 patients with BRAF V600E wild-type metastatic melano-
ma who had not previously received treatment, patients were
randomized to ipilimumab plus or minus concurrent and adju-
vant nivolumab. Patients who received combination therapy,
compared to ipilimumab alone, had a better objective response
rate to therapy (61 vs 11 %, p<0.001), and better progression-
free survival (not reached vs 4.4 months, p<0.001), with an
acceptable safety profile [28]. While these response rates are
promising, it is clear that not all patients benefit from this im-
munotherapy. It is therefore important to be able to identify
those patients likely to respond to treatment. It is hoped that
results from ongoing trials will elucidate patient or tumor char-
acteristics that are predictive of a high likelihood of response.
Promising combinations of immunotherapy
and radiation
Multiple groups have recently published case reports of
abscopal responses in distal tumor sites (outside of the radiation
therapy field) following local radiotherapy in combination with
immunotherapy [11, 15, 26]. Reynders et al. reviewed the cur-
rent data on the abscopal effect, consisting of one retrospective
clinical study and a total of 23 case reports. In these reports, the
median time to abscopal response was 5 months, with a median
of 13 months after abscopal response before disease progres-
sion or end of follow-up [31]. In the single retrospective clinical
study, 21 patients who progressed after ipilimumab alone were
then treated with palliative radiotherapy. Median time to pro-
gression from the first dose of ipilimumab was 4 months (range
2.3–6 months), and median time from start of ipilimumab to
radiation was 5 months (range 3.4–8 months). Of 21 patients,
11 (52 %) showed an abscopal effect including two patients
with stable disease. In the patients who had an abscopal effect,
median overall survival was increased versus those without an
abscopal effect (22.4 vs 8.3 months, p=0.002). Of note, these
patients were treated with sequential, rather than concurrent
therapy in this study, but it is likely that there may have been
residual effects of the ipilimumab at the time of irradiation [12,
31]. In addition, in a recent phase I clinical trial performed at
the University of Pennsylvania, 22 patients with metastatic
melanoma were treated with hypofractionated radiation to a
single lesion in combination with four cycles of ipilimumab.
In terms of best clinical response, 18 % of patients had a partial
response and 18 % had stable disease. Sixty-four percent of
patients did not respond to this combination therapy and had
progressive disease [42].
The mechanism responsible for the abscopal response is
thought to be related to the effector T cell response, as animal
models have shown that it is not possible to induce an
abscopal response in athymic mice. Increased levels of IL-
12, IFN-γ, and IL-2 also play an important role in the cyto-
toxic T cell response and associated abscopal effect [3]. A
variety of preclinical and clinical studies have been performed
to try to better elucidate the underlying mechanism of action
of the abscopal response [16]. A number of preclinical studies
have demonstrated that combination therapy with radiation
and CTLA-4 blockade can lead to a significant survival ben-
efit compared with monotherapy alone [5]. In patients, immu-
nologic correlates of the abscopal effect were reported initially
by Postow et al., in which they report clinical responses to
radiation and concurrent ipilimumab correlating with an in-
crease in antibody titers to NY-ESO-1 and other tumor-
associated antigens, as well as increase in CD4+ T cell and
myeloid lineage activation, and corresponding decline in
myeloid-derived suppressor cells [27]. These results have
led to an ongoing phase II randomized trial of patients (with
at least two separate measurable sites of disease), in which
patients are randomized to ipilimumab alone or with radiation,
with immune monitoring of T cell and B cell responses to
melanoma-associated tumor antigens [6].
Predictors of response to therapy
While there is considerable excitement surrounding initial re-
sponse rates and durable responses to immunotherapy, as well
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as combination therapy with immunotherapy and radiation ther-
apy, at present it is not known how to identify those patients who
are likely to respond to treatment. There are also no validated
biomarkers to detect the development of a potentially clinically
meaningful antitumor immune response in treated patients. This
is currently an active area of investigation. Early reports indicat-
ed that patients with metastatic melanoma who have less than
1000 lymphocytes per cubic millimeters, particularly after the
first or second course of ipilimumab, have a worse prognosis
[21]. The most consistently reported predictor of response to
PD-1 pathway blockade is pretreatment tumor PD-L1 expres-
sion. Taube et al. found that infiltrating immune cells were geo-
graphically associated with PD-L1 expression and that expres-
sion of PD-L1 on tumor cells and immune infiltrates represents
an Bimmune-active tumor milieu.^ Tumor PD-L1 expression
correlated with response to anti-PD-1 therapy [39].
Tumeh et al. reported that in patients treated with
pembrolizumab for advanced melanoma, responding patients
had proliferation of intratumoral CD8+ T cells, which directly
correlated with radiographic reduction in tumor size.
Responding patients had higher pretreatment numbers of
CD8, PD1, and PD-L1 expressing cells, both at the tumor
margin and inside of the tumors [41]. A predictive model
was created based on CD8 expression at the invasive margin
and was validated in an independent set of 15 patients, with
authors concluding that tumor regression after PD-1 blockade
requires preexisting CD8+ T cells, which are negatively reg-
ulated by a PD-1/PD-L1-mediated adaptive resistance [41]. In
this study, the preexisting density of CD8+ T cells was more
closely correlatedwith response to anti-PD-1 therapy thanwas
PD-L1 expression. Also of note, responders had significantly
higher levels of pSTAT1+ at the invasive margin in the area of
CD8+ T cell infiltration before and during treatment, with
significantly higher levels of pSTAT1 expression during treat-
ment compared to baseline [41].
In an effort to better determine which patients with meta-
static melanoma will respond to CTLA-4 blockade and may
benefit from treatment with ipilimumab, Snyder et al. per-
formed whole-exome sequencing from tumors and matched
blood samples to analyze somatic mutations and potential
neoantigens generated from these mutations. They found that
a high mutational load was associated with benefit from treat-
ment with CTLA-4 blockade, and also found a strong
neoantigen landscape in patients who respond to CTLA-4
blockade, with some homology to viral and bacterial antigens.
This neoantigen landscape was validated in another set of 39
patients. Response peaked at 60 weeks following treatment
[37]. Similarly, in a study of patients with NSCLC, higher
numbers of mutations and a corresponding increase in
neoantigens was found to correlate with clinical response in
patients treated with anti-PD-1 pembrolizumab [32].
In a recent report by Johnson et al., outcomes of 229 pa-
tients with melanoma treated with immune therapies were
compared by tumor genotype. They found that benefit from
anti-PD-1/PD-L1 was significantly greater in patients with
NRAS mutations. NRAS-mutant melanoma was found to
have higher PD-L1 expression compared with other geno-
types, though this was not statistically significant [19].
Data presented at the SITC 2014 meeting included phase
IIb results from the TIME study examining TG4010 immuno-
therapy combined with initial chemotherapy in advanced
NSCLC. TG4010 is a modified vaccine vector encoding the
entire tumor antigenMUC1 and IL-2 [18, 30]. Previous phase I
data had shown a survival advantage with the addition of
TG4010 to chemotherapy in patients with normal levels of
circulating activated NK cells (CD16+ CD56+ CD69+), but
not in patients with high levels of NK cells. A prospective study
incorporating the previous results enrolled patients with ad-
vanced MUC1-expressing NSCLC to receive TG4010 versus
placebo with first-line platinum-based chemotherapy. In a sub-
group analysis of 221 patients, patients with normal levels of
pretreatment-activated NK cells and patients with
nonsquamous histology showed a significant improvement in
PFS, with a trend toward OS benefit. Patients with both normal
levels of pretreatment-activated NK cells and nonsquamous
histology benefitted the most. A large phase III trial is now
ongoing to further investigate this finding [18, 30].
Another study examining biomarkers and characteristics of
response to PD-1 immune checkpoint blockade in NSCLC
patients was also recently reported at the 2014 SITC meeting.
Only two markers of response have thus far been shown to
correlate with higher response rates to PD-1 blockade in
NSCLC patients: PD-L1 expression and smoking status, with
smokers more likely to respond. However, these are not spe-
cific markers, and PD-L1-negative patients and never smokers
may sometimes respond to PD-1 blockade. In addition, PD-L1
expression may be inconsistent between the primary site and
metastatic sites of disease [1]. A recent study showed that in
the context of combination immunotherapy for melanoma,
PD-L1 expression in the tumor and absolute lymphocyte
count did not appear to be predictive markers of tumor re-
sponse [28]. The authors hypothesize that in combination ther-
apy, it is possible that anti-CTLA-4 therapy drives T cell in-
filtration into tumors, creating a more optimal environment for
anti-PD-1 therapy to work [18].
The benefits of anti-PD-1/anti-PD-L1 therapy have been
reported in other diseases in addition to melanoma and
NSCLC. For example, treatment with the anti-PD-L1 anti-
body MPDL3280A has been shown to reduce metastatic le-
sions in patients with renal cell carcinoma and urothelial blad-
der cancer [14]. Herbst et al. reported that responses were seen
in patients with tumors of multiple types including melanoma,
renal cell carcinoma, and NSCLC expressing high levels of
PD-L1, particularly when PD-L1 was expressed by tumor-
infiltrating immune cells. They note that response to therapy
was associated with T-helper type 1 gene expression, CTLA4
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expression, and the absence of CX3CL1 in baseline tumor
specimens [14]. In gene expression studies, baseline IFN-γ
and CXCL9 were significantly higher in study patients who
had a partial or complete response (PR/CR) to treatment ver-
sus those with progressive disease, and IFN-γ, IDO1, and
CXCL9 were significantly higher in study patients with mel-
anoma who had a PR/CR to treatment versus those with pro-
gressive disease. Patients who progressed through treatment
most commonly lacked PD-L1 upregulation by tumor cells or
tumor-infiltrating immune cells [14]. In examining bio-
markers found in the blood, they found a rise in ITAC and
IL-18, as well as an increase in activated cytotoxic T lympho-
cytes and decrease in IL-6. However, these changes did not
clearly distinguish responders from nonresponders.
Powles et al. also examined the safety and activity of the
anti-PD-L1 antibodyMPDL3280A and found a high response
rate in patients with metastatic bladder cancer, with durable
ongoing responses in 16 of 17 responders. They found no
cytokines to be predictive of response. They did observe tran-
sient elevations in IL-18 and IFN-γ by cycle 2, as well as an
increase in proliferating CD8+ cells in treated patients, but
these changes were not specific to the responders [29]. High
levels of PD-L1 in the tumor were again found to predict
better response to therapy.
Recent data presented at the ASCO 2015 meeting also
supports the use of immunotherapy in a variety of tumor types
and suggests potential biomarkers of response. In the
CheckMate 057 phase III randomized trial, patients with ad-
vanced nonsquamous NSCLC who had progressed on
platinum-based doublet chemotherapy were randomized to
receive nivolumab or docetaxel. The trial was closed early
due to a survival advantage in the nivolumab group, with a
median overall survival (OS) of 12.2 versus 9.4 months in the
docetaxel group. All subgroups of patients had a survival ben-
efit from treatment, except for those with tumors with EGFR
mutations. PD-L1 was a strong predictor of response to treat-
ment with nivolumab, with median OS of 17.2, 18.2, and
19.4 months for patients whose tumors had at least 1, 5, and
10 % of cells staining positive for PD-L1, respectively [25].
Other results presented at ASCO support a potential role
for PD-1 blockade in advanced hepatocellular carcinoma
(HCC). In a phase I/II study of nivolumab in advanced
HCC, 19% of 42 patients had a response with tumor reduction
greater than 30 %, with two complete responses, and durable
responses lasting beyond 12 months for 50 % of patients.
Treatment was well tolerated, including among patients with
hepatitis B or C infections. Overall survival at 1 year was 62%
[9].
Results from an expansion cohort of KEYNOTE-012 trial
also presented at ASCO showed a benefit to pembrolizumab
in patients with recurrent or metastatic squamous cell carcino-
ma of the head and neck. The overall objective response rate
was 24.8 %, and 57 % of patients experienced some tumor
shrinkage, with roughly equivalent response rates in HPV-
positive and HPV-negative tumors. Responses were often
long-lasting, and less than 10 % of patients experienced sig-
nificant side effects from treatment [35].
Results from a phase II study presented at ASCO showed
that tumors with mismatch repair (MMR) deficiencies respond
better to treatment with pembrolizumab than those that were
MMR-proficient. Among three cohorts of patients, including
25 patients with MMR-deficient CRC, MMR-proficient CRC,
and MMR-deficient cancers including uterus, stomach, pros-
tate, duodenum, and bile ducts, those patients with MMR-
deficient tumors had a response rate to pembrolizumab of ap-
proximately 60 %, as compared with 0 % for patients with
MMR-proficient tumors. Of note, MMR deficiency is associ-
ated with high mutational burden, consistent with previous
studies showing better response to anti-PD-1 therapy in tumors
with a high number of mutations [9].
Response to combination therapy
In other settings, biomarkers have been used to predict re-
sponse to systemic therapy plus radiation. Elevated
neutrophil/lymphocyte ratio before chemoradiation has been
reported to predict poor pathologic tumor response and sur-
vival after preoperative chemoradiation for rectal cancer [20].
Preclinical markers of response to therapy support p53 as
playing an important role in the abscopal response following
local tumor irradiation [2, 38]. In the Postow et al. report on
markers of abscopal responses, the presence of NY-ESO-1
antibodies after radiotherapy enhanced the efficiency of
ipilimumab. Following radiotherapy, the antibody titer rose
by 30-fold [28]. Also noted was an increase in CD4+ T cells
after radiation therapy, as well as a decrease in myeloid-
derived suppressor cells prior to identification of an abscopal
effect. Following radiation and ipilimumab, titers against mel-
anoma antigen-A2 also increased [27]. These findings led to
an ongoing phase II trial of patients with at least two separate
measurable sites of disease, with patients randomized to
ipilimumab alone or with radiation, with immune monitoring
of T cell and B cell response to melanoma-associated tumor
antigens [6].
Blockade of TGF-β has been shown to contribute to the
induction of abscopal effects, and also to overcome local im-
munosuppression [8]. In a preclinical model, Demaria et al.
found a synergistic benefit to TGF-β blockade combined with
local tumor irradiation, with increase in tumor infiltrating lym-
phocytes. Loss of therapeutic benefit was seen after depletion
of CD4 or CD8 Tcells. Upregulation of immune system path-
way genes occurred in response to combination therapy, and
the addition of anti-PD-1 therapy provided further benefit [8].
Importantly, expression of coinhibitorymolecules such as PD-
L1 have been shown to be induced in tumor cells after local
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high-dose radiation therapy [7], which has potential implica-
tions for the optimal sequencing of these therapeutic agents.
In studies of patients with metastatic hepatocellular carci-
noma, there have been reports of changes in serum cytokines
before and after radiation therapy. Ohba et al. reported an
abscopal effect occurring with decreased AFP and concomi-
tant increase of TNF-α after radiation therapy [24]. Nakanishi
et al. also studied serum cytokines before and after radiation
therapy, and did not find an increase in TNF-α, but did note an
increase in IL-18 before and after radiotherapy [23].
In a phase I clinical trial of 22 patients with metastatic
melanoma at the University of Pennsylvania, patients were
treated with ipilimumab plus local radiation therapy to a single
lesion, and the unirradiated lesion/s were assessed for re-
sponse. The best response to therapy was a partial response
in 18 % of patients and stable disease in another 18 % of
patients. Twyman-Saint Victor et al. then used a correspond-
ing melanoma mouse model and found that low CD8+/Treg
ratio predicted resistance of melanoma to anti-CTLA4 therapy
and radiation, and profiling of these tumors revealed high
levels of tumor PD-L1. The defect in CD8+ T cell accumula-
tion in resistant tumors was related to increased PD-L1 expres-
sion on the melanoma cells. Genetic silencing of PD-L1
caused the melanomas to again become sensitive to anti-
CTLA-4 therapy and radiation. Addition of anti-PD-L1 IgG
increased the number of active CD8+ Tcells [42]. The authors
reported that combining PD1, PD-L1, and CTLA4-mediated
immune checkpoint inhibition with radiation promoted effec-
tive antitumor immunity through a distinct, nonredundant
mechanism. As noted by Twyman-Saint Victor et al. and
reviewed by Leavy, complete responses were CD8+ T cell
dependent, and failure to increase the ratio of CD8+ CD44+
T cells to Tregs (CD8/Treg ratio) within the tumor infiltrating
lymphocyte population predicted resistance [22, 42]. They
found that the lack of increase in the CD8+/Treg ratio in re-
sistant tumor cells was due to a failure of CD8+ T cells to
accumulate in tumors, since Tregs did decrease, as in sensitive
tumors, and high PD-L1 expression on tumor cells was found
to cause reduced CD8+ T cell accumulation. Markers of ex-
haustion and activation in peripheral T cells, as well as chang-
es in the CD8+/Treg ratio as above in the peripheral blood,
were shown to be predictive of response in mice to this im-
munotherapy. In the clinical trial patients, high PD-L1 expres-
sion on pretreatment tumor biopsies was associated with per-
sistent T cell exhaustion and disease progression after combi-
nation treatment, suggesting that combination therapy
targeting both PD-L1 and CTLA-4 may be important for the
optimization of this immunotherapy approach [22, 42].
Current studies
Animal studies are ongoing to characterize the cellular immune
responses to systemic therapies that may allow for identification
of candidate genes and cellular toxicity pathways that are impor-
tant for response [10]. For example, Frick et al. isolated
splenocytes from 36 isogenic strains of mice in the development
of a drug screening platform and examined interstrain differences
in the viability of immune cells following chemotherapy, with
phenotypes quantified with flow cytometry. As expected, more
targeted agents BEZ-235 and selumetinib were less toxic to nor-
mal immune cells than standard chemotherapeutic anthracycline
agents. They also found that heritability of the viability of im-
mune cells after exposure to therapy was higher for
anthracyclines than targeted agents between generations [10].
There are multiple ongoing clinical trials testing the combi-
nation of immunotherapy and radiation, as recently summa-
rized by Crittenden et al. [4]. A variety of studies are also
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Fig. 1 Potential positive (green)
and negative (red) predictors of
outcome in anti-PD-1
immunotherapy. Some
biomarkers have also been shown
for other types of immunotherapy,
though there is variation by
immunotherapy and tumor type.
Most of these biomarkers are
measured from
immunohistochemistry (IHC) of
tumor biopsy sections; activated
NK cells and lymphocyte counts
are derived from peripheral blood
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examining ways to convert nonresponders to responders fol-
lowing immunotherapy [26]. An immunotherapy biomarkers
task force has been established to further investigate bio-
markers of response in order to better select patients for therapy,
and ultimately learn how to steer the immune system in the
direction of meaningful and durable clinical responses [36].
Summary
In summary, the early data on biomarkers of response to im-
munotherapy suggest that pretreatment tumor PD-L1 levels, as
well as preexisting numbers of CD 8+ T cells and levels of
pSTAT1+ cells at the tumor margin may be important predic-
tors of response (Fig. 1). However, the PD-L1 level may be less
important in the context of combination therapy with anti-
CTLA-4 and anti-PD-1 therapy. Higher tumor mutational load
andMMR deficiency also appears to correlate with response to
therapy. Other potential markers of response with more limited
data at this time include IFN-γ, IDO1, CXCL9, and IL-18. The
CD8+/Treg ratio appears to play a role in response to treatment
and may be related to PD-L1 levels. Further work is necessary
tomore fully elucidate biomarkers of response in order to better
predict which patients are likely to respond to immunother-
apies, and to assess early patient response to treatment.
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